Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - ASEAN

ASEAN

The Other Vaccines market in ASEAN is expected to reach a revenue of US$0.57bn in 2024.
It is projected to display an annual growth rate (CAGR 2024-2029) of 11.22%, which will lead to a market volume of US$0.97bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue of US$24,730.00m in 2024.
Despite the challenges faced by ASEAN countries in the Other Vaccines market, significant progress has been made in improving accessibility and affordability for the population.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in ASEAN has been experiencing growth in recent years due to various factors.

Customer preferences: Customers in ASEAN countries have become increasingly aware of the importance of vaccines in preventing diseases and maintaining good health. This has led to a rise in demand for vaccines, including Other Vaccines. Additionally, governments in the region have been promoting vaccination campaigns, which has further increased demand for vaccines.

Trends in the market: In Indonesia, the Other Vaccines market has been growing due to the increasing prevalence of infectious diseases such as dengue fever and Japanese encephalitis. The government has also been promoting vaccination campaigns to prevent these diseases. In Thailand, the market has been growing due to the increasing popularity of medical tourism, with many tourists seeking vaccination services.

Local special circumstances: In the Philippines, the Other Vaccines market has been growing due to the increasing prevalence of infectious diseases such as typhoid fever and hepatitis A. The government has also been promoting vaccination campaigns to prevent these diseases. In Malaysia, the market has been growing due to the increasing number of expatriates and foreign workers, who require vaccination services.

Underlying macroeconomic factors: The growing middle class in ASEAN countries has led to an increase in demand for healthcare services, including vaccination services. Additionally, the increasing prevalence of infectious diseases in the region has led to a rise in demand for vaccines. The growing medical tourism industry in the region has also contributed to the growth of the Other Vaccines market. Finally, government initiatives to promote vaccination campaigns have further increased demand for vaccines.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.